Asset supplier Amgen and investor Kleiner Perkins tight-lipped on Atara startup
This article was originally published in Scrip
Executive Summary
If loose lips sink ships then Amgen and its venture capital partner Kleiner Perkins Caufield & Byers (KPCB) have nothing to worry about when it comes to their new startup Atara Biotherapeutics, which will focus on drug development for chronic diseases in therapeutic areas that include nephrology and oncology.